For the latest openings visit the Careers section of our website CPL Biologicals launches Cadiflu-S,World`s First Virus Like Particle(VLP) Vaccine for Seasonal Influenza
The public at large is cautioned of fraudulent activities and false commitments using the name of Cadila.

News & Events

  • CPL Biologicals launches Cadiflu-S, World’s First Virus Like Particle (VLP) Vaccine for Seasonal Influenza Read More >>
POLYCAP
Therapeutic segment: Cardiac
Active Ingredient: Simvastatin BP ..20mg, Ramipril IP ..5mg,Atenolol IP ..50mg, Hydrochlorothiazide IP ..12.5mg, Aspirin IP (Enteric coated tablet)..100mg, Excipients ..q.s.
Pack Details: 15 C

According to Cadila Pharmaceuticals commissioned and sponsored ‘The Indian Polycap Study’ PolycapTM brings down the risk of coronary heart disease by 62% and stroke by 48%. PolycapTM can reduce multiple risk factors for cardiovascular diseases such as lowering the blood pressure, the heart rate, the lipids and decreasing the stickiness of the platelets. ‘The polypill – can reduce cardiovascular events by more than 80% in healthy individuals.’ This was the conclusion of the study of the effect of the Polycap on blood pressure, lipids, heart rate, and urinary thromboxane B2, and of the assessment of its tolerability.

Counterfeit Drugs: In case of any information on /or availability of counterfeit products... Read More © 2018 Cadila Pharmaceuticals all right reserved
Corporate identification No : U24231GJ1991PLC015132
Cadila Pharmaceuticals